Nothing Special   »   [go: up one dir, main page]

WO2005118548A1 - Substituted 1,2,3,4-tetrahydroisoquinoline derivatives - Google Patents

Substituted 1,2,3,4-tetrahydroisoquinoline derivatives Download PDF

Info

Publication number
WO2005118548A1
WO2005118548A1 PCT/EP2005/001879 EP2005001879W WO2005118548A1 WO 2005118548 A1 WO2005118548 A1 WO 2005118548A1 EP 2005001879 W EP2005001879 W EP 2005001879W WO 2005118548 A1 WO2005118548 A1 WO 2005118548A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
disorders
syndrome
phenyl
tetrahydroisoquinoline
Prior art date
Application number
PCT/EP2005/001879
Other languages
French (fr)
Inventor
Thomas Weller
Ralf Koberstein
Hamed Aissaoui
Martine Clozel
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0508263-3 priority Critical patent/BRPI0508263B8/en
Priority to NZ550216A priority patent/NZ550216A/en
Priority to CN200580006491XA priority patent/CN1926109B/en
Priority to US10/598,449 priority patent/US7763638B2/en
Priority to ES05804734.1T priority patent/ES2533389T3/en
Priority to DK05804734.1T priority patent/DK1751111T3/en
Priority to SI200531944T priority patent/SI1751111T1/en
Priority to JP2007501172A priority patent/JP4094050B2/en
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to AU2005250077A priority patent/AU2005250077B2/en
Priority to PL05804734T priority patent/PL1751111T3/en
Priority to CA2557163A priority patent/CA2557163C/en
Priority to EP05804734.1A priority patent/EP1751111B1/en
Publication of WO2005118548A1 publication Critical patent/WO2005118548A1/en
Priority to IL177798A priority patent/IL177798A/en
Priority to NO20064347A priority patent/NO337299B1/en
Priority to US12/815,605 priority patent/US20100256182A1/en
Priority to HRP20150371TT priority patent/HRP20150371T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel substituted 1,2,3,4-tetrahydroisoquinoline derivatives of the general formula (I) and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I), and especially their use as orexin receptor antagonists.
  • Orexins are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al, Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G-protein-coupled receptors (OXi and OX 2 receptors).
  • the orexin-1 receptor (OXi) is selective for OX-A
  • the orexin-2 receptor (OX 2 ) is capable to bind OX-A as well as OX-B.
  • Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al, Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R.M. et al, Cell, 1999, 98, 437-451).
  • Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies such as depression; anxiety; addictions, obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Tourette syndrome; eating disorders; sleep disorders; cardiovascular diseases, diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome
  • HIV post-chemotherapy pain
  • post-stroke pain post-operative pain
  • neuralgia conditions associated with visceral pain such as irritable bowel syndrome, migraine and angina
  • urinary bladder incontinence e.g. urge incontinence
  • tolerance to narcotics or withdrawal from narcotics sleep apnea; narcolepsy; insomnia; parasomnia
  • neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure disorders and other diseases related to general orexin system dysfunction.
  • the present invention provides substituted 1,2,3,4-tetrahydroisoquinoline derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders or sleep disorders.
  • some low molecular weight compounds are known having a potential to antagonise either specifically OX] or OX 2 , or both receptors at the same time.
  • SmithKline Beecham reported phenylurea, phenylthiourea and cinnamide derivatives as OXi selective antagonists (WO99/09024, WO00/47576 and WO00/47580).
  • Actelion Pharmaceuticals Ltd. claimed 1,2,3,4-tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical composition (WO01/68609). Furthermore, the use of solution-phase chemistry for the lead optimization of 1,2,3,4-tetrahydroisoquinoline derivatives as potential orexin receptor antagonists has been reported (Chimia, 2003, 57, 1-6).
  • cytochrome P450 cytochrome P450
  • the drug oxidation by CYP enzymes should be appropriate with respect to the desired therapeutic indication and a high inhibition of CYP enzymes should be avoided. This is due to the problem of drug-drug interaction , i.e. the increased plasma concentration of a drug by inhibition of a CYP enzyme from another drug.
  • the predominant drug-metabolising CYP 450s are CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 which represents about 30% of the total CYP enzymes.
  • Many drugs are transformed by CYP3A4 and some drugs have no other metabolism pathway than this specific cytochrome. As a result, a low CYP3A4 inhibition is absolutely crucial for a chemical entity to become a drug candidate.
  • the compounds of the present invention have low affinities against CYP3A4. Further, it has also been observed that these compounds were active after oral administration. Compounds of the present invention are therefore useful for the treatment of diseases such as, for example, eating disorders or sleep disorders.
  • alkyl alone or in combination with other groups, means a straight-chain or branched-chain alkyl group with 1 to 6 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched
  • C ⁇ -C 6 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, the isomeric pentyls, the isomeric hexyls, preferably methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl or tert-butyl.
  • alkoxy alone or in combination with other groups, means a R-O- group wherein R is an alkyl group as above-defined, such as methoxy, ethoxy, w-propoxy, isopropoxy, n- butoxy, isobutoxy, sec-butoxy and tert-butoxy, preferably methoxy and ethoxy.
  • salts encompasses either salts with inorganic acids or organic acids like hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, pamoic acid, stearic acid, methanesulfonic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, trifluoroacetic acid, and the like that are non toxic to living organisms or in case the compound of formula (I) is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like.
  • salt selection for basic drugs Int. J. Pharm. (1986), 33, 201-217.
  • Salt-forming groups are groups or radicals having basic or acidic properties.
  • Compounds having at least one basic group or at least one basic radical, for example amino, a secondary amino group not forming a peptide bond or a pyridyl radical, may form acid addition salts, for example with inorganic acids.
  • acid addition salts for example with inorganic acids.
  • mono- or poly-acid addition salts may be formed.
  • Compounds having acidic groups may form metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri-(2-hydroxy- ethyl)-amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'- dimethylpiperazine. Mixtures of salts are possible.
  • Compounds having both acidic and basic groups can form internal salts.
  • a first aspect of the invention consists of novel substituted 1,2,3,4-tetrahydroisoquinoline derivatives of the following general formula (I):
  • R 1 and R 2 independently represent hydrogen or C ⁇ -C 4 alkoxy
  • R 3 represents C ⁇ -C 6 -alkyl
  • X represents -CH- or a nitrogen atom.
  • Also encompassed by the present invention are compounds of formula I and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, eso forms and pharmaceutically acceptable salts, solvent complexes and mo ⁇ hological forms, thereof.
  • Any reference to a compound of General Formula (I) is to be understood as referring also to configurational isomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates, as well as salts, especially pharmaceutically acceptable salts, solvent complexes, and morphological forms, as appropriate and expedient.
  • the present invention encompasses also solvation complexes of compounds of general Formula (I).
  • the solvation can be effected in the course of the manufacturing process or can take place separately, e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of general Formula (I).
  • the invention further encompasses different morphological forms, e.g crystalline forms, of compounds of general Formula (I) and their salts and solvation complexes. Particular heteromorphs may exhibit different dissolution properties, stability profiles, and the like, and are all included in the scope of the present invention.
  • Preferred substituted 1,2,3,4-tetrahydroisoquinoline derivatives are those wherein R 1 and R 2 both represent a C1-C4 alkoxy group, particularly a methoxy group.
  • X represents -CH-. In another preferred embodiment, X represents a nitrogen atom.
  • R 3 represents a methyl group.
  • R 1 and R 2 represent a methoxy group
  • X represents -CH-
  • R 3 represents Ci-C ⁇ -alkyl
  • Examples of preferred compounds are selected from the group consisting of: 2- ⁇ 6,7-Dimethoxy-l- [2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl ⁇ - N-methyl-2-phenyl-acetamide;
  • the compounds pursuant to general formula (I) are useful in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as ⁇ untington's disease and Tourette syndrome; diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hype ⁇ rolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome (anos
  • HIV post-chemotherapy pain
  • post-stroke pain post-operative pain
  • neuralgia conditions associated with visceral pain such as irritable bowel syndrome; migraine and angina
  • urinary bladder incontinence e.g. urge incontinence
  • tolerance to narcotics or withdrawal from narcotics sleep disorders; eating disorders; cardiovascular disorders; neurodegenerative disorders; sleep apnea; narcolepsy; insomnia; parasomnia; and neurodegenerative disorders including nosological entities such as disinhibition-dementia- " park ⁇ ns ⁇ ism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure . disorders and other diseases related to general orexin system dysfunctions.
  • Compounds of the general formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of eating disorders or sleep disorders.
  • Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
  • This pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance.
  • Sleep disorders include insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome.
  • Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness.
  • a further object of the invention is a pharmaceutical composition containing at least one compound according to general formula (I) and a pharmaceutically acceptable carrier material.
  • Another object of the present invention is a method for the treatment or prophylaxis of diseases, which are related to the orexin receptors such as eating disorders or sleep disorders comprising the administration to a patient of a therapeutically effective amount of a 1,2,3,4- tetrahydroisoquinoline derivative according to general formula (I).
  • this amount is comprised between 1 mg and 1000 mg per day, particularly from 2 mg to 500 mg per day, more particularly from 5 mg to 200 mg per day.
  • the present invention also concerns a process for the preparation of a pharmaceutical composition
  • a pharmaceutical composition comprising a 1,2,3,4-tetrahydroisoquinoline derivative according to general formula (I) by mixing one or more active ingredients according to general formula (I) with a carrier material in a manner known per se.
  • the compounds of general formula (I) and their pharmaceutically acceptable salts can be used as medicament (e.g. in the form of pharmaceutical preparations).
  • the pharmaceutical preparations can be administered enterally, such as orally (e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories).
  • the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions), or topically, e.g. in the form of ointments, cream or oils.
  • the compounds of general formula (I) and their pharmaceutically acceptable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragees, and hard gelatine capsules.
  • Lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragees, and hard gelatine capsules.
  • Suitable adjuvants for soft gelatine capsules are for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
  • Suitable adjuvants for the production of solutions and syrups are, for example, water, alcohol, polyols, saccharose, invert sugar, glucose etc.
  • Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
  • Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
  • the compounds of this invention can also be administered in sustained release forms by using known sustained release drug delivery systems.
  • a further object of the invention is a process for the preparation of 1,2,3,4-tetrahydroiso- quinoline derivatives according to general formula (I).
  • Compounds according to general formula (I) of the present invention are prepared according to the general sequence of reactions outlined in the schemes below wherein X, R 1 , R 2 and R 3 are as defined in general formula (I).
  • the compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.
  • Enantiomerically highly enriched 1,2,3,4- tetrahydroisoquinolines are obtained by a transfer hydrogenation of the respective 3,4 dihydroisoquinoline in the presence of a chiral Ru(II)-complex (chiral catalyst), which was originally described by R. ⁇ oyori et al. (J. Am. Chem. Soc. 1996, 118, 4916-4917 and WO 97/20789).
  • the chiral catalyst (Ru(II) complex) used is as follows:
  • 1,2,3,4-tetrahydroisoquinoline intermediates according to the invention can be converted to compounds of general formula (I) following one of the three different synthetic routes a) b) or c).
  • route a the 1,2,3,4- tetrahydroisoquinoline is alkylated with a substituted 2-bromo-acetic acid methyl ester. The obtained ester is hydrolyzed to the corresponding acid and finally converted to the amide by an amide-coupling reaction with the desired amine in the presence of a coupling reagent.
  • route b) the side-chain is introduced by a direct alkylation of the respective 1,2,3,4- tetrahydroisoquinoline with a 2-bromo-acetamide derivative:
  • 1,2,3,4-tetrahydroisoquinoline derivatives of general formula (I) can also be prepared in a stereoselective manner starting from enantiomerically pure methyl (S)-(+)-mandelate following route c) (cf. Scheme 3 hereinafter).
  • ester By treating the ester with an alcoholic amine solution the corresponding amide is obtained which can be tosylated with p-toluenesulphonyl chloride.
  • the tosylate is coupled with a 1,2,3,4-tetrahydroisoquinoline derivative to give the respective compound of general formula (I).
  • the 1,2,3,4-tetrahydroisoquinoline derivatives exemplified in this invention may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e., reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art using routine optimisation procedures.
  • Lithium hydroxide monohydrate (330 mg) is added in one portion to a solution of 3-(6- trifluoromethyl-pyridin-3-yl)-propionic acid methyl ester (610 mg) in a mixture of THF (15 mL) and water (5 mL). The mixture is stirred for 20h at RT. DCM and aqueous HCl (1.0 M) are added, the layers are separated and the aqueous layer is extracted twice with DCM. The combined organic extracts are dried over MgSO 4 and concentrated in vacuo to give the desired propionic acid as a beige solid.
  • Methyl (S)-(+)-mandelate (17 g) is dissolved in a solution of methylamine in methanol (230 L, 2.0 M) and kept at RT for 1 d. Another portion of methylamine in methanol (10 mL, 2.0 M) is added. A third portion of methylamine in methanol (10 mL, 2.0 M) is added one day later. After additional 24 h the solvents are removed in vacuo to give the desired mandelamide as pale yellow crystals, which are used without further purification.
  • LC-MS: rt 0.52 min, 166 (M+l, ES+).
  • a solution of mesitylenesulfonyl chloride (3.09 g) in THF (150 ml) is added drop wise to a suspension of (1R, 2R)-l,2-diphenyl-ethane-l,2-diamine (3.00 g), diisopropylethylamine (3.87 mL) and potassium carbonate (3.12 g) in a mixture of THF (120 mL) and DMF (30 L).
  • 3h water (300 L) and ethyl acetate (300 L) are added, the layers are separated and the aqueous layer is extracted three times with ethyl acetate (3x300 mL).
  • This compound is prepared by reaction of 3,4-dimethoxyphenylethylamine and 4-(tri- fluoromethyl)-hydrocinnamic acid.
  • LC-MS: rt 0.97 min, 382 (M+l, ES+).
  • This compound is prepared by reaction of 3,4-dimethoxyphenylethylamine and 3-(6- trifluoromethyl-pyridin-3-yl)-propionic acid.
  • LC-MS: rt 0.88 min, 383 (M+l, ES+).
  • This compound is prepared by cyclisation of N-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(4- trifluoromethyl-phenyl)-propionamide.
  • This compound is prepared by reaction of N-[2-(3,4-dimethoxy-phenyI)-ethyl]-3-(4- trifluoromethyl-phenyl)-propionamide.
  • LC-MS: rt 0.85 min, 366 (M+l, ES+).
  • This compound is prepared by reaction of N-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(6- trifluoromethyl-pyridin-3-yl)-propionamide.
  • Dichloro-(/ cymene)ruthenium (II) dimer (0.20 mmol) is added to a solution of N-((1R,2R)- 2-amino-l,2-diphenyI-ethyl)-2,4,6-trimethylbenzene-sulfonamide (0.40 mmol) and triethylamine (0.80 mmol) in acetonitrile (3.0 L).
  • the mixture is stirred for lh at 80°C and added to a solution of the respective dihydroisoquinoline (28.0 mmol) in dichloromethane (30 L).
  • An azeotropic mixture of formic acid and triethylamine (5:2, 14 mL) is added (gas evolution).
  • aqueous ⁇ aHC0 3 solution 200 mL is added to the dark red solution.
  • the layers are separated, the aqueous layer is extracted twice with DCM (2x200 L) and the combined organic extracts are concentrated in vacuo.
  • the residue is dissolved in isopropanol (1600 mL) and treated with a solution of HCl in isopropanol (5-6 M, 10 mL).
  • the obtained hydrochloride salt is recrystallized to give the respective 1,2,3,4- tetrahydroisoquinoline with high enantiomeric excess as determined by chiral HPLC.
  • the hydrochloride salt is converted to the free base by extraction with sat.
  • This compound is prepared by transfer hydrogenation of 6,7-dimethoxy-l-[2-(4- trifluoromethyl-phenyl)-ethyl]-3,4-dihydroisoquinoline.
  • dichloro(p-cymene)ruthenium (II) dimer (0.15 mmol) is added to a solution ofN-((lR,2R)-2-amino-l,2-diphenyl-ethyl)-2,4,6-trimethyl-benzene-sulfonamide (0.30 mmol) and triethylamine (0.60 mmol) in acetonitrile (3.3 mL).
  • the mixture is stirred for lh at 80°C. A portion of this solution (0.10 mL) is added to the solution of the respective dihydroisoquinoline (described above).
  • This compound is prepared by reaction of 6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)- ethyl]-l,2,3,4-tetrahydroisoquinoline with ⁇ -bromo-phenyl-acetic acid methyl ester.
  • LC-MS: rt 0.93 min, 514 (M+l, ES+).
  • This compound is prepared by reaction of 6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3- yl)-ethyl]- 1 ,2,3,4-tetrahydroisoquinoline with ⁇ -bromo-phenyl-acetic acid methyl ester.
  • LC-MS: rt 1.68 min, 515 (M+l, ES+).
  • This compound is prepared by reaction of (lS)-6,7-dimethoxy-l-[2-(4-trifluorornethyl- phenyl)-ethyl]-l,2,3,4-tetrahydroisoquinoline with ⁇ -bromo-phenyl-acetic acid methyl ester.
  • This compound is prepared by saponification of ⁇ 6,7-dimethoxy-l-[2-(4-trifluoromethyl- phenyl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl ⁇ -phenyl-acetic acid methyl ester.
  • LC-MS: rt 0.88 min, 500 (M+l, ES+).
  • This compound is prepared by saponification of ⁇ 6,7-dimethoxy-l-[2-(6-trifluoromethyl- pyridin-3-yl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl ⁇ -phenyl-acetic acid methyl ester.
  • LC-MS: rt 1.18 min, 499 (M-l, ES-), 501 (M+l, ES+).
  • This compound is prepared by saponification of ⁇ (lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl- phenyl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl ⁇ -phenyl-acetic acid methyl ester.
  • LC-MS: rt 0.88 min, 500 (M+l, ES+).
  • the orexin receptor antagonistic activity of the compounds of general formula (I) is determined in accordance with the following experimental method.
  • Chinese hamster ovary (CHO) cells expressing the human orexin- 1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 ⁇ g/ml G418, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 10 % inactivated fetal calf serum (FCS).
  • FCS fetal calf serum
  • the cells are seeded at 80O00 cells / well into 96-well black clear bottom sterile plates (Costar) which have been precoated with 1% gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents are from Gibco BRL.
  • the seeded plates are incubated overnight at 37 C C in 5% CO 2 .
  • Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol: water (1 :1), diluted in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
  • BSA bovine serum albumin
  • Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES.
  • BSA bovine serum albumin
  • HEPES 5 mM probenecid (Sigma) and 3 ⁇ M of the fluorescent calcium indicator fluo-3 AM (1 mM stock solution in DMSO with 10% pluronic acid) (Molecular Probes) is added to each well.
  • the 96-well plates are incubated for 60 min at 37° C in 5% C0 2 .
  • the loading solution is then aspirated and cells are washed 3 times with 200 ⁇ l HBSS containing 2.5 mM probenecid, 0.1% BSA, 2 mM HEPES. 100 ⁇ l of that same buffer is left in each well.
  • FLIPR Fluorescent Imaging Plate Reader
  • antagonists are added to the plate in a volume of 50 ⁇ l, incubated for 20 min and finally 100 ⁇ l of agonist is added.
  • IC 50 value the concentration of compound needed to inhibit 50 % of the agonistic response
  • CYP inhibition studies are performed using human liver microsomes (pool of 10 individuals), literature-established CYP isoform-selective substrates and quantification by either LC-MS/MS (for CYP3A4 and CYP2C9) or conventional HPLC with fluorimetric detection (for CYP2D6).
  • the specific probes were midazolam l'-hydroxylation for CYP3A4, dextrometho ⁇ han 3-hydroxylation for CYP2D6 and diclofenac 4'-hydroxylation for CYP2C9.
  • the objective of the present test is to record the circadian behavioral activity of rats after oral administration of a compound according to general formula (I) of the invention.
  • Psychitropic drugs such as antidepressants, antipsychotics, sleep inducers or psychostimulants are well known to reduce or enhance home cage activity and body temperature following oral administration to laboratory animals.
  • Thermoregulation is a complex process that contributes to homeostasis by coordinating metabolism, energy balance and behaviour. Body temperature changes with circadian behavioural activity and increases when locomotion increases. These two parameters were measured by telemetry in conscious freely moving Wistar rats. Anaesthetized animals were implanted, under aseptic conditions, with a body temperature/activity telemetric device into the peritoneal cavity. More than two weeks after the implantation of the telemetry system, data were collected at 5 minutes intervals during 96 hours. Hourly means were calculated for each rat.
  • the first 48 h were used as an internal control trace and drug effects were compared to vehicle placebo. This method is validated pharmacologically by measuring amplitude and time course of both hypoactivity and hypothermia induced by GABA-A receptor modulators such as zolpidem.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)

Abstract

The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives of formula (I) wherein R1, R2, R3 and X are as defined in the claims, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to a mammal.

Description

Substituted 1.2.3.4-Tetrahydroisoquinoline Derivatives
The present invention relates to novel substituted 1,2,3,4-tetrahydroisoquinoline derivatives of the general formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I), and especially their use as orexin receptor antagonists.
Orexins (orexin A or OX-A and orexin B or OX-B) are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al, Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G-protein-coupled receptors (OXi and OX2 receptors). The orexin-1 receptor (OXi) is selective for OX-A, and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B. Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al, Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R.M. et al, Cell, 1999, 98, 437-451).
Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies such as depression; anxiety; addictions, obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Tourette syndrome; eating disorders; sleep disorders; cardiovascular diseases, diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep apnea; narcolepsy; insomnia; parasomnia; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure disorders and other diseases related to general orexin system dysfunction.
The present invention provides substituted 1,2,3,4-tetrahydroisoquinoline derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders or sleep disorders. Up to now, some low molecular weight compounds are known having a potential to antagonise either specifically OX] or OX2, or both receptors at the same time. In some patent applications, e.g. SmithKline Beecham reported phenylurea, phenylthiourea and cinnamide derivatives as OXi selective antagonists (WO99/09024, WO00/47576 and WO00/47580). More recently, in their patent applications, SmithKline Beecham suggests 2-amino- methylpiperidine derivatives (WOO 1/96302), 3-aminomethyl-morpholine derivatives (WO02/44172) and N-aroyl cyclic amines (WO02/090355, WO03/002559 and WO03/002561) as orexin receptor antagonists. In WO01/85693, Banyu Pharmaceuticals claimed N-acyltetrahydroisoquinoline derivatives. Other orexin receptor antagonists such as novel benzazepine derivatives are disclosed in WO02/051838.
Actelion Pharmaceuticals Ltd. claimed 1,2,3,4-tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical composition (WO01/68609). Furthermore, the use of solution-phase chemistry for the lead optimization of 1,2,3,4-tetrahydroisoquinoline derivatives as potential orexin receptor antagonists has been reported (Chimia, 2003, 57, 1-6).
It is well known that the adequate regulation of plasma concentrations of a drug during the treatment period is one of the crucial aspects in therapy. One very important mechanism for this regulation is the oxidation of a drug substance by cytochrome P450 (CYP) enzymes. The drug oxidation by CYP enzymes should be appropriate with respect to the desired therapeutic indication and a high inhibition of CYP enzymes should be avoided. This is due to the problem of drug-drug interaction , i.e. the increased plasma concentration of a drug by inhibition of a CYP enzyme from another drug.
The predominant drug-metabolising CYP 450s are CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 which represents about 30% of the total CYP enzymes. Many drugs are transformed by CYP3A4 and some drugs have no other metabolism pathway than this specific cytochrome. As a result, a low CYP3A4 inhibition is absolutely crucial for a chemical entity to become a drug candidate.
It has now been found that the compounds of the present invention have low affinities against CYP3A4. Further, it has also been observed that these compounds were active after oral administration. Compounds of the present invention are therefore useful for the treatment of diseases such as, for example, eating disorders or sleep disorders.
The following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.
The term "alkyl", alone or in combination with other groups, means a straight-chain or branched-chain alkyl group with 1 to 6 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched
Cι-C6 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, the isomeric pentyls, the isomeric hexyls, preferably methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl or tert-butyl. The term "alkoxy", alone or in combination with other groups, means a R-O- group wherein R is an alkyl group as above-defined, such as methoxy, ethoxy, w-propoxy, isopropoxy, n- butoxy, isobutoxy, sec-butoxy and tert-butoxy, preferably methoxy and ethoxy.
The expression "pharmaceutically acceptable salts" encompasses either salts with inorganic acids or organic acids like hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, pamoic acid, stearic acid, methanesulfonic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, trifluoroacetic acid, and the like that are non toxic to living organisms or in case the compound of formula (I) is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like. For other examples of pharmaceutically acceptable salts, reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
Salt-forming groups are groups or radicals having basic or acidic properties. Compounds having at least one basic group or at least one basic radical, for example amino, a secondary amino group not forming a peptide bond or a pyridyl radical, may form acid addition salts, for example with inorganic acids. When several basic groups are present mono- or poly-acid addition salts may be formed.
Compounds having acidic groups, such as a carboxy group or a phenolic hydroxy group, may form metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri-(2-hydroxy- ethyl)-amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'- dimethylpiperazine. Mixtures of salts are possible.
Compounds having both acidic and basic groups can form internal salts.
For the purposes of isolation or purification, as well as in the case of compounds that are used further as intermediates, it is also possible to use pharmaceutically unacceptable salts, e.g. the picrates. Only pharmaceutically acceptable, non-toxic salts may be used for therapeutic purposes, however, and those salts are therefore preferred. A first aspect of the invention consists of novel substituted 1,2,3,4-tetrahydroisoquinoline derivatives of the following general formula (I):
Figure imgf000006_0001
(I) wherein
R1 and R2 independently represent hydrogen or Cι-C4 alkoxy;
R3 represents Cι-C6-alkyl;
X represents -CH- or a nitrogen atom.
Also encompassed by the present invention are compounds of formula I and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, eso forms and pharmaceutically acceptable salts, solvent complexes and moφhological forms, thereof.
Any reference to a compound of General Formula (I) is to be understood as referring also to configurational isomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates, as well as salts, especially pharmaceutically acceptable salts, solvent complexes, and morphological forms, as appropriate and expedient.
As above-mentioned, the present invention encompasses also solvation complexes of compounds of general Formula (I). The solvation can be effected in the course of the manufacturing process or can take place separately, e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of general Formula (I). The invention further encompasses different morphological forms, e.g crystalline forms, of compounds of general Formula (I) and their salts and solvation complexes. Particular heteromorphs may exhibit different dissolution properties, stability profiles, and the like, and are all included in the scope of the present invention.
Preferred substituted 1,2,3,4-tetrahydroisoquinoline derivatives are those wherein R1 and R2 both represent a C1-C4 alkoxy group, particularly a methoxy group.
In a preferred embodiment according to the invention, X represents -CH-. In another preferred embodiment, X represents a nitrogen atom.
In another preferred embodiment according to the invention, R3 represents a methyl group.
In a particularly preferred embodiment according to the invention, R1 and R2 represent a methoxy group, X represents -CH- and R3 represents Ci-Cβ-alkyl.
Examples of preferred compounds are selected from the group consisting of: 2-{6,7-Dimethoxy-l- [2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl}- N-methyl-2-phenyl-acetamide;
2-{6,7-Dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-lH-iso-quinolin- 2-yl}-N-methyl-2-phenyl-acetamide.
The compounds pursuant to general formula (I) are useful in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Ηuntington's disease and Tourette syndrome; diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hypeφrolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hypeφrolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. by HIV; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome; migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; eating disorders; cardiovascular disorders; neurodegenerative disorders; sleep apnea; narcolepsy; insomnia; parasomnia; and neurodegenerative disorders including nosological entities such as disinhibition-dementia- "parkϊnsόήism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure . disorders and other diseases related to general orexin system dysfunctions.
Compounds of the general formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of eating disorders or sleep disorders.
Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa. This pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance.
Sleep disorders include insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome. Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness. A further object of the invention is a pharmaceutical composition containing at least one compound according to general formula (I) and a pharmaceutically acceptable carrier material.
Another object of the present invention is a method for the treatment or prophylaxis of diseases, which are related to the orexin receptors such as eating disorders or sleep disorders comprising the administration to a patient of a therapeutically effective amount of a 1,2,3,4- tetrahydroisoquinoline derivative according to general formula (I).
In a preferred embodiment of the invention, this amount is comprised between 1 mg and 1000 mg per day, particularly from 2 mg to 500 mg per day, more particularly from 5 mg to 200 mg per day.
The present invention also concerns a process for the preparation of a pharmaceutical composition comprising a 1,2,3,4-tetrahydroisoquinoline derivative according to general formula (I) by mixing one or more active ingredients according to general formula (I) with a carrier material in a manner known per se.
The compounds of general formula (I) and their pharmaceutically acceptable salts can be used as medicament (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered enterally, such as orally (e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions), or topically, e.g. in the form of ointments, cream or oils.
The compounds of general formula (I) and their pharmaceutically acceptable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragees, and hard gelatine capsules. Lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragees, and hard gelatine capsules. Suitable adjuvants for soft gelatine capsules, are for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
Suitable adjuvants for the production of solutions and syrups are, for example, water, alcohol, polyols, saccharose, invert sugar, glucose etc. Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc. Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
The above-described components for orally administered or injectable compositions are merely representative examples. Further materials as well as processing techniques and the 1 ike are set out in Remington 's Pharmaceutical Sciences, 20th Edition, 2001 , Marck Publishing Company, Easton, Pennsylvania, which is incoφorated herein by reference.
The compounds of this invention can also be administered in sustained release forms by using known sustained release drug delivery systems.
A further object of the invention is a process for the preparation of 1,2,3,4-tetrahydroiso- quinoline derivatives according to general formula (I). Compounds according to general formula (I) of the present invention are prepared according to the general sequence of reactions outlined in the schemes below wherein X, R1, R2 and R3 are as defined in general formula (I). The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.
As described in Scheme 1 below, the key-intermediates in the synthesis of compounds of the general formula (I) are 1-substituted 3,4-dihydroisoquinoline derivatives. These compounds are prepared either by cyclisation of N-phenethyl-propionamides with POCl3 or by alkylation of l-methyl-3,4-dihydroisoquinolines with alkyl bromides. The 3,4-dihydroisoquinolines obtained are reduced to 1,2,3,4-tetrahydroisoquinolines with sodium borohydride to give the products as racemic mixtures. Enantiomerically highly enriched 1,2,3,4- tetrahydroisoquinolines are obtained by a transfer hydrogenation of the respective 3,4 dihydroisoquinoline in the presence of a chiral Ru(II)-complex (chiral catalyst), which was originally described by R. Νoyori et al. (J. Am. Chem. Soc. 1996, 118, 4916-4917 and WO 97/20789). The chiral catalyst (Ru(II) complex) used is as follows:
Figure imgf000010_0001
Figure imgf000011_0001
Scheme 1
As illustrated in Scheme 2 and Scheme 3 below, 1,2,3,4-tetrahydroisoquinoline intermediates according to the invention can be converted to compounds of general formula (I) following one of the three different synthetic routes a) b) or c). In route a), the 1,2,3,4- tetrahydroisoquinoline is alkylated with a substituted 2-bromo-acetic acid methyl ester. The obtained ester is hydrolyzed to the corresponding acid and finally converted to the amide by an amide-coupling reaction with the desired amine in the presence of a coupling reagent. In route b), the side-chain is introduced by a direct alkylation of the respective 1,2,3,4- tetrahydroisoquinoline with a 2-bromo-acetamide derivative:
Figure imgf000012_0001
Scheme 2
1,2,3,4-tetrahydroisoquinoline derivatives of general formula (I) can also be prepared in a stereoselective manner starting from enantiomerically pure methyl (S)-(+)-mandelate following route c) (cf. Scheme 3 hereinafter). By treating the ester with an alcoholic amine solution the corresponding amide is obtained which can be tosylated with p-toluenesulphonyl chloride. In a last step the tosylate is coupled with a 1,2,3,4-tetrahydroisoquinoline derivative to give the respective compound of general formula (I).
Figure imgf000013_0001
Scheme 3
The 1,2,3,4-tetrahydroisoquinoline derivatives exemplified in this invention may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e., reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art using routine optimisation procedures.
Experimental section:
Abbreviations: aq. aqueous at atmosphere
BSA Bovine Serum Albumine CHO Chinese Hamster Ovary d Day(s)
DCM Dichloromethane
DIPEA Diisopropylethylamine
DMAP N,N-dimethyl-4-aminopyridine
DMF Dimethylformamide
DMSO Dimethylsulfoxide
EA Ethyl acetate
EDC l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide
ES Electron Spray
FCS Fetal Calf Serum
FLIPR Fluorescent Imaging Plate Reader h hour
HBSS Hank's Balanced Salt Solution
HEPES 4-(2-Hydroxyethy l)-piperazine- 1 -ethanesulfonic acid
HOBt Hydroxybenzotriazol
HPLC High Performance Liquid Chromatography
Hex Hexane
HV High Vacuum conditions
LC Liquid Chromatography
LDA Lithium diisopropylamide
MeOH Methanol min minutes
MS Mass Spectroscopy p.o. per os prep. preparative
PyBOP Benzotriazole-l-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
Rf Retention front
RT Room temperature rt retention time sat. saturated tic thin layer chromatography
THF Tetrahydrofuran Chemistry
The following examples illustrate the preparation of pharmacologically active compounds of the invention but do not at all limit the scope thereof.
All temperatures are stated in °C.
All analytical and preparative HPLC investigations on non-chiral phases are performed using RP-C18 based columns. Analytical HPLC investigations are performed on two different instruments with cycle-times of ~2.5 min and -3.5 min respectively. For HPLC separations on chiral phases a Chiralcel OD column from Daicel Chemical Industries is used. Compounds are characterized by Η-NMR (300MHz) or 13C-NMR (75MHz) (Varian Oxford; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet; q = quartet, m = multiplet, b = broad, coupling constants are given in Hz); by LC-MS, rt is given in min; by TLC (TLC-plates from Merck, Silica gel 60 F254); or by melting point.
A. Synthesis of propionic acid derivatives:
1. Synthesis of 3-(6-trifluoromethyl-pyridin-3-vD-propionic acid:
1.1 Synthesis of 3-(6-trifluoromethyl-pyridin-3-yl)-acrylic acid methyl ester:
Figure imgf000015_0001
A solution of 6-trifluoromethyl-pyridine-3-carbaldehyde (570 mg) in DCM (1.0 mL) is added to a solution of (triphenyl-λ5-phosphanylidene)-acetic acid methyl ester (990 mg) in DCM (2.5 ml). The mixture is stirred under nitrogen at reflux for 20h and concentrated in vacuo. The residue is purified by flash chromatography (EA/heptane 3/7) to give the desired unsaturated ester as a white solid. 1H-NMR (300MHz, CDC13): δ = 3.85 (s, 3H), 6.59 (d, J = 16.2 Hz, IH), 7.70 (d, J = 16.2 Hz,
IH), 7.71 (d, J = 8.1 Hz, IH), 7.98 (dd, J = 8.1 Hz, J = 2.1 Hz, IH), 8.84 (bs, IH).
1.2 Synthesis of 3-(6-trifluoromethyl-pyridin-3-yl)-propionic acid methyl ester:
Figure imgf000016_0001
A solution of 3-(6-trifluoromethyl-pyridin-3-yl)-acrylic acid methyl ester (720 mg) in methanol (5.0 mL) is treated with Pd/C (10%, 240 mg) and stirred under a hydrogen atmosphere (~1 bar) at RT for 20h. The suspension is filtered through Celite and concentrated in vacuo to give the propionic acid ester as a colorless oil.
Η-NMR (300MHz, CDC13): δ = 2.69 (t, J = 7.4 Hz, 2H), 3.05 (t, J = 7.4 Hz, 2H), 3.68 (s, 3H), 7.60 (d, J = 7.8 Hz, IH), 7.71 (bd, J = 8.1 Hz, IH), 8.58 (bs, IH).
1.3. Synthesis of 3-(6-trifluoromethyl-pyridin-3-yl)-propionic acid:
Figure imgf000016_0002
Lithium hydroxide monohydrate (330 mg) is added in one portion to a solution of 3-(6- trifluoromethyl-pyridin-3-yl)-propionic acid methyl ester (610 mg) in a mixture of THF (15 mL) and water (5 mL). The mixture is stirred for 20h at RT. DCM and aqueous HCl (1.0 M) are added, the layers are separated and the aqueous layer is extracted twice with DCM. The combined organic extracts are dried over MgSO4 and concentrated in vacuo to give the desired propionic acid as a beige solid.
Η-NMR (300MHz, CDC13): δ = 2.75 (t, J = 7.4 Hz, 2H), 3.06 (t, J = 7.4 Hz, 2H), 7.62 (d, J = 8.1 Hz, IH), 7.73 (bd, J = 8.1 Hz, IH), 8.62 (bs, IH).
B. Synthesis of 2-bromo-acetamide derivatives:
1. Synthesis of 2-bromo-N-methyl-2-phenyl-acetamide:
1.1. Synthesis of N-hydroxy-N-methyl-2-phenyl-acetamide:
Figure imgf000017_0001
At 0°C phenyl-acetyl chloride (1 1.2 mL) is added drop wise to a solution of N-methyl- hydroxylamine hydrochloride (7.07 g) and triethylamine (59 mL) in DCM (300 mL). After stirring for 90 min a sat. aqueous NaHCO3 solution is added, the layers are separated and the aqueous layer is extracted twice with DCM (2x200 mL). The solvents are removed in vacuo and the residue is purified by flash chromatography (EA/heptane 1/1) to give the desired N- hydroxy-acetamide as a colorless liquid. LC-MS: rt = 0.63 min, 166 (M+l, ES+).
.2. Synthesis of 2-bromo-N-methyl-2-phenyl-acetamide:
Figure imgf000017_0002
At 0°C triethylamine (5.49 mL) is added to a solution of N-hydroxy-N-methyl-2-phenyl- acetamide (6.5 g) in DCM (200 mL). The mixture is treated drop wise with a solution of methanesulfonyl chloride (3.21 mL) in DCM (60 mL). After 2 h water (150 mL) is added, the layers are separated and the aqueous layer is extracted twice with EA (2x100 mL). The organic extracts are combined and concentrated in vacuo to give the crude mesylate as a pale yellow oil.
The mesylate is dissolved in acetonitrile (200 mL). Lithium bromide (15.3 g) is added and the reaction mixture is treated with ultrasound for 5 min. After addition of diisopropyl-ethylamine (6.78 mL) the mixture is again treated with ultrasound for 5 min and stirred for additional 60 min at room temperature. Water (150 mL) and ethyl acetate (200 mL) are added, the layers are separated and the aqueous layer is extracted twice with ethyl acetate (2x200 mL). The combined organic extracts are concentrated in vacuo and purified by flash chromatography (ethyl acetate/heptane 2:3) to give the desired bromide as a white solid. LC-MS: rt = 0.75 min, 228 (M+l, ES+).
C. Synthesis of toluene-4-sulfonic acid (S)-methylcarbamoyl-phenyl-methyl ester:
1. Synthesis of (S)-2-hydroxy-N-methyl-2-phenyl-acetamide:
Figure imgf000018_0001
Methyl (S)-(+)-mandelate (17 g) is dissolved in a solution of methylamine in methanol (230 L, 2.0 M) and kept at RT for 1 d. Another portion of methylamine in methanol (10 mL, 2.0 M) is added. A third portion of methylamine in methanol (10 mL, 2.0 M) is added one day later. After additional 24 h the solvents are removed in vacuo to give the desired mandelamide as pale yellow crystals, which are used without further purification. LC-MS: rt = 0.52 min, 166 (M+l, ES+).
2. Synthesis of toluene-4-sulfonic acid (S)-methylcarbamoyl-phenyl-methyl ester:
Figure imgf000018_0002
At RT DIPEA (2.74 mL) and DMAP (145 mg) are added to a solution of (S)-2-hydroxy-N- methyl-2-phenyl-acetamide (2.4 g) in DCM (50 mL). The mixture is treated portionwise with p-toluenesulfonyl chloride (2.75 g) and kept for 2 h at RT. The solvent is removed in vacuo and the residue is dissolved in ethyl acetate. The solution is washed twice with sat. ΝaHC03 solution and once with brine, the solvents are removed in vacuo and the residue is recrystallized from ethyl acetate/tert. -butylmethylether to give the tosylate as white crystals. LC-MS: rt = 0.93 min, 320 (M+l, ES+). D. Synthesis of /V-((lR,2R)-2-amino-l,2-diphenyl-ethyI)-2,4,6-trimethyl-benzene- sulfonamide (catalyst precursor):
Figure imgf000019_0001
At 0°C a solution of mesitylenesulfonyl chloride (3.09 g) in THF (150 ml) is added drop wise to a suspension of (1R, 2R)-l,2-diphenyl-ethane-l,2-diamine (3.00 g), diisopropylethylamine (3.87 mL) and potassium carbonate (3.12 g) in a mixture of THF (120 mL) and DMF (30 L). After 3h water (300 L) and ethyl acetate (300 L) are added, the layers are separated and the aqueous layer is extracted three times with ethyl acetate (3x300 mL). The solvents are removed in vacuo and the residue is purified by preparative HPLC chromatography. To remove the formic acid the obtained product is extracted with sat. NaHCO3 solution/ethyl acetate to give the mono-sulfonamide as a white solid. LC-MS: rt = 0.82 min, 395 (M+l, ES+).
E. Synthesis of phenylethylamides (general procedure):
A solution of the respective phenylethylamine (110 mmol) in toluene (350 mL) is treated with the respective propionic acid derivative (110 mmol), refluxed for 90h in the presence of a Dean-Stark trap and cooled slowly to RT. The precipitate is filtered off and dried under vacuum to give the desired amide.
1. Synthesis ofN-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(4-trifluoromethyl-phenyl)- propionamide:
Figure imgf000019_0002
This compound is prepared by reaction of 3,4-dimethoxyphenylethylamine and 4-(tri- fluoromethyl)-hydrocinnamic acid. LC-MS: rt = 0.97 min, 382 (M+l, ES+).
2. Synthesis of N-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(6-trifluoromethyl-pyridin-3-yl)- propionamide:
Figure imgf000020_0001
This compound is prepared by reaction of 3,4-dimethoxyphenylethylamine and 3-(6- trifluoromethyl-pyridin-3-yl)-propionic acid. LC-MS: rt = 0.88 min, 383 (M+l, ES+).
F. Synthesis of 3,4-dihydroisoquinoline derivatives via amide-cyclisation (general procedure): Phosphorus oxychloride (123 mmol) is added to a suspension of the respective amide (55.3 mmol) in acetonitrile (300 mL). The mixture is refluxed for 90 min and the solvents are removed in vacuo. Methanol (100 L) is added and evaporated again. The obtained product is recrystallized from dioxane or dioxane/ethanol. After filtration the obtained hydrochloride salt is converted to the free base by addition of saturated aqueous ΝaHC03 solution and extraction with dichloromethane. The solvents are removed in vacuo to give the respective dihydroisoquinoline.
1. Synthesis of 6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydroiso- quinoline:
Figure imgf000021_0001
This compound is prepared by cyclisation of N-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(4- trifluoromethyl-phenyl)-propionamide.
LC-MS: rt = 0.81 min, 364 (M+l, ES+).
2. Synthesis of 6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro- isoquinoline:
Figure imgf000021_0002
This compound is prepared by cyclisation of N-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(6- trifluoromethyl-pyridin-3-yl)-propionamide. LC-MS: rt = 0.73 min, 365 (M+l, ES+)
G. Synthesis of 1,2,3,4-tetrahydroisoquinolines:
1. Synthesis of 1.2.3.4-tetrahydroisoquinolines via Bischler-Νapieralski-reaction (general procedure):
To a suspension of the respective amide (44.8 mmol) in acetonitrile (500 mL) is added phosphorus oxychloride (224 mmol). The mixture is heated to reflux for 2h and the solvent is removed in vacuo. The resulting oil is taken up in either toluene or MeOH (20 L), evaporated to dryness, dissolved in MeOH (200 mL) and cooled to 0°C. ΝaBH4 (135 mmol) is added in small portions and the reaction mixture is stirred for 2h. The solvent is removed in vacuo, EA (400 mL) and water (400 mL) are added, the layers are separated and the aqueous layer is extracted three times with EA (3x200 mL). The combined organic extracts are concentrated in vacuo to give the following 1,2,3,4-tetra-hydroisoquinolines as racemic mixtures, which are purified by crystallization of the hydrochloride salt from isopropanol.
1.1. Synthesis of rac-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-l,2,3,4- tetrahydroisoquinoline:
Figure imgf000022_0001
This compound is prepared by reaction of N-[2-(3,4-dimethoxy-phenyI)-ethyl]-3-(4- trifluoromethyl-phenyl)-propionamide. LC-MS: rt = 0.85 min, 366 (M+l, ES+).
1.2. Synthesis of 6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-l,2,3,4- tetrahydroisoquinoline:
Figure imgf000022_0002
This compound is prepared by reaction of N-[2-(3,4-dimethoxy-phenyl)-ethyl]-3-(6- trifluoromethyl-pyridin-3-yl)-propionamide.
LC-MS: rt = 0.73 min, 367 (M+l, ES+). 2. Synthesis of 1,2,3,4-tetrahydroisoquinolines via transfer hydrogenation (general procedure):
Dichloro-(/ cymene)ruthenium (II) dimer (0.20 mmol) is added to a solution of N-((1R,2R)- 2-amino-l,2-diphenyI-ethyl)-2,4,6-trimethylbenzene-sulfonamide (0.40 mmol) and triethylamine (0.80 mmol) in acetonitrile (3.0 L). The mixture is stirred for lh at 80°C and added to a solution of the respective dihydroisoquinoline (28.0 mmol) in dichloromethane (30 L). An azeotropic mixture of formic acid and triethylamine (5:2, 14 mL) is added (gas evolution). After 90 min a sat. aqueous ΝaHC03 solution (200 mL) is added to the dark red solution. The layers are separated, the aqueous layer is extracted twice with DCM (2x200 L) and the combined organic extracts are concentrated in vacuo. The residue is dissolved in isopropanol (1600 mL) and treated with a solution of HCl in isopropanol (5-6 M, 10 mL). The obtained hydrochloride salt is recrystallized to give the respective 1,2,3,4- tetrahydroisoquinoline with high enantiomeric excess as determined by chiral HPLC. The hydrochloride salt is converted to the free base by extraction with sat. NaHCO3 solution/dichloromethane. The absolute configuration of the respective product is assigned in analogy to the literature (N. Uematsu, A. Fujii, S. Hashiguchi, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1996, 118, 4916-4917).
2.1 Synthesis of (lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-l,2,3,4- tetrahydroisoquinoline:
Figure imgf000023_0001
This compound is prepared by transfer hydrogenation of 6,7-dimethoxy-l-[2-(4- trifluoromethyl-phenyl)-ethyl]-3,4-dihydroisoquinoline.
LC-MS: rt = 0.80 min, 366 (M+l, ES+). chiral HPLC: rt = 12.0 min (hexane/ethanol 9/1; enantiomer: rt = 17.1 min). 2.2 Synthesis of (lS)-6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-l,2,3,4- tetrahydroisoquinoline:
Figure imgf000024_0001
This compound is prepared by transfer hydrogenation of 6,7-dimethoxy-l-[2-(6-trifluoro- methyl-pyridin-3-yl)-ethyl]-3,4-dihydroisoquinoline. LC-MS: rt = 0.73 min, 367 (M+l, ES+). chiral HPLC: rt = 10.9 min (hexane/ethanol 4/1; enantiomer: rt = 24.4 min).
3. Synthesis of 1,2,3,4-tetrahydroisoquinolines via alkylation of l-methyl-3.4-dihydro- isoquinolines (general procedure):
At 0°C a solution of n-BuLi in hexane (1.6M, 0.63 mmol) is added drop wise to a mixture of 6,7-dimethoxy-l-methyl-3,4-dihydroisoquinoline (0.50 mmol) and diisopropylamine (0.63 mmol) in THF (1.0 mL). The reaction mixture is stirred at RT for lh and added at 0°C to a solution of the respective benzyl bromide (0.50 mmol) in THF (1.0 mL). The solution is stirred for lh, warmed up to RT and diluted with DCM (3.0 mL).
In a second flask dichloro(p-cymene)ruthenium (II) dimer (0.15 mmol) is added to a solution ofN-((lR,2R)-2-amino-l,2-diphenyl-ethyl)-2,4,6-trimethyl-benzene-sulfonamide (0.30 mmol) and triethylamine (0.60 mmol) in acetonitrile (3.3 mL). The mixture is stirred for lh at 80°C. A portion of this solution (0.10 mL) is added to the solution of the respective dihydroisoquinoline (described above). An azeotropic mixture of formic acid and triethylamine (5:2, 0.3 mL) is added (gas evolution). After 2d the mixture is concentrated in vacuo and purified by prep. HPLC to give the respective 1,2,3,4-tetra-hydroisoquinoline.
The enantiomeric excess is determined by chiral HPLC. The absolute configuration of the respective product is assigned in analogy to the literature
(N. Uematsu, A. Fujii, S. Hashiguchi, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1996, 1 18,
4916-4917).
3.1. Synthesis of (lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-l,2,3,4- tetrahydroisoquinoline:
Figure imgf000025_0001
This compound is prepared by alkylation of 6,7-dimethoxy-l-methyl-3,4-dihydroiso- quinoline with l-bromomethyl-4-trifluoromethyl-benzene. LC-MS: rt = 0.80 min, 366 (M+l, ES+). chiral HPLC: rt = 12.0 min (hexane/ethanol 9/1; enantiomer: rt = 17.1 min).
H. Synthesis of (3,4-dihydro-lH-isoquinolin-2-yl)-phenyl-acetic acid methyl ester derivatives (general procedure):
DIPEA (43.0 mmol) and α-bromo-phenyl-acetic acid methyl ester (21.5 mmol) are added successively to a solution of the respective 1,2,3,4-tetrahydroisoquinoline (21.5 mmol) in either THF, dioxane or toluene (150 mL). The mixture is refluxed for 20h and allowed to reach RT. Water (250 mL) and EA (200 mL) are added, the layers were separated and the aqueous layer is extracted twice with EA (2x100 mL). The combined organic extracts are concentrated in vacuo and either purified by flash chromatography or used without further purification. The following ester derivatives described hereinafter are obtained.
1. Synthesis of {6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid methyl ester.
Figure imgf000026_0001
This compound is prepared by reaction of 6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)- ethyl]-l,2,3,4-tetrahydroisoquinoline with α-bromo-phenyl-acetic acid methyl ester. LC-MS: rt = 0.93 min, 514 (M+l, ES+).
2. Synthesis of {6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid methyl ester:
Figure imgf000026_0002
This compound is prepared by reaction of 6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3- yl)-ethyl]- 1 ,2,3,4-tetrahydroisoquinoline with α-bromo-phenyl-acetic acid methyl ester. LC-MS: rt = 1.68 min, 515 (M+l, ES+).
3. Synthesis of {(lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid methyl ester:
Figure imgf000026_0003
This compound is prepared by reaction of (lS)-6,7-dimethoxy-l-[2-(4-trifluorornethyl- phenyl)-ethyl]-l,2,3,4-tetrahydroisoquinoline with α-bromo-phenyl-acetic acid methyl ester.
LC-MS: rt = 0.93 min, 514 (M+l, ES+).
I. Synthesis of (3,4-dihydro-lH-isoquinolin-2-yl)-phenyl-acetic acid derivatives (general procedure):
A solution of sodium hydroxide in water (2.0M, 50 mL) is added to a solution of the respective ester (21.5 mmol) in methanol (400 mL). The mixture is heated to 60°C and stirred for 20h. Most of the methanol is removed in vacuo and the residue is taken up in sodium hydroxide solution (2.0M, 20 mL), water (100 mL) and DCM (100 L). The layers are separated and the aqueous layer is extracted three times with DCM (3x100 L). The combined organic extracts are concentrated in vacuo to give the respective carboxylic acid, which is used without further purification:
1. Synthesis of {6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid:
Figure imgf000027_0001
This compound is prepared by saponification of {6,7-dimethoxy-l-[2-(4-trifluoromethyl- phenyl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl}-phenyl-acetic acid methyl ester. LC-MS: rt = 0.88 min, 500 (M+l, ES+).
2. Synthesis of {6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid:
Figure imgf000028_0001
This compound is prepared by saponification of {6,7-dimethoxy-l-[2-(6-trifluoromethyl- pyridin-3-yl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl}-phenyl-acetic acid methyl ester. LC-MS: rt = 1.18 min, 499 (M-l, ES-), 501 (M+l, ES+).
3. Synthesis of {(lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid:
Figure imgf000028_0002
This compound is prepared by saponification of {(lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl- phenyl)-ethyl]-3,4-dihydro-lH-isoquinolin-2-yl}-phenyl-acetic acid methyl ester. LC-MS: rt = 0.88 min, 500 (M+l, ES+).
Example 1: Synthesis of 2-(6,7-dimethoxy-l-r2-(4-trifluoromethyl-phenyl)-ethyll-3.4- dihydro-lH-isoquinolin-2-yl)-N-methyl-2-phenyl-acetarnide
Figure imgf000028_0003
At 0°C methylamine hydrochloride (15.0 mmol) and NaHC03 (20.0 mmol) are added to a solution of {6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid (10.0 mmol) in DMF (200 L). After 15 min HOBt (12.0 mmol) and EDC hydrochloride (22.0 mmol) are added. The mixture is stirred for 10 min and kept for additional 14h at 0°C without stirring. Water (100 mL), EA (300 L) and cyclohexane (100 mL) are added, the layers are separated and the aqueous layer is extracted twice with EA/cyclohexane 3: 1 (2x150 L). The combined organic extracts are washed with a sat. aqueous NaHC03 solution (100 mL) and brine (100 mL) and dried over Na2S04. The solvents are removed in vacuo and the residue is purified by flash chromatography (gradient: EA/heptane 1/2 to EA/ethanol/heptane 2/1/2) to give the desired amides as mixture of all 4 possible stereoisomers. LC-MS: rt = 0.89 min, 513 (M+l, ES+).
Example 2: Synthesis of (2R)-2-((lS)-6.7-dimethoxy-l-f2-(4-trifluoromethyl-phenyl)-ethyl]- 3,4-dihydro-lH-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide
Figure imgf000029_0001
a) Procedure I (via amide-coupling):
At 0°C methylamine hydrochloride (23.7 mmol) and ΝaHC03 (2.01 g, 23.9 mmol) are added to a solution of {(lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid (21.5 mmol) in DMF (300 mL). After 5 min HOBt (23.8 mmol) and EDC hydrochloride (47.6 mmol) are added. The mixture is stirred for 2h and kept for additional 14h at 0°C without stirring. Water (300 L) and EA (300 L) are added, the layers are separated and the aqueous layer is extracted three times with EA (3x150 L). The combined organic extracts are washed with water (3x100 mL) and brine (100 mL). The solvents are removed in vacuo and the residue is purified by flash chromatography (EA/heptane 3/2) to give the desired amides as separated dia-stereoisomers. b) Procedure II (via alkylation with a bromide derivative): DIPEA (1 19 mmol) is added to a solution of 2-bromo-N-methyl-2-phenyl-acetamide (59.6 mmol) in THF (150 mL). A solution of (lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyI-phenyl)- ethyl]- 1,2,3,4-tetrahydroisoquinoline (62.7 mmol) in THF (200 mL) is added and the reaction mixture is stirred at 60°C for 7d. Ethyl acetate (200 mL) and a sat. aqueous solution of ΝaHCO3 (200 mL) are added, the layers are separated and the aqueous layer is extracted twice with ethyl acetate (2xl00mL). The combined organic extracts are washed with water (3x50 mL), dried over MgSO4 and concentrated in vacuo. The residue is purified by flash chromatography (ethyl acetate/heptane 3/2) to give the desired amides as separated diastereoisomers.
c) Procedure III (via alkylation with a tosylate derivative):
A solution of (lS)-6,7-dimethoxy-l-[2-(4-trifluoromethyl-phenyl)-ethyl]-l,2,3,4-tetra- hydroisoquinoline (100 mg), toluene-4-sulfonic acid (S)-methylcarbamoyl-phenyl-methyl ester (100 mg) and DIPEA (0.065 mL) in butanone (5.0 mL) is heated to reflux for 3 d and cooled to RT. Ethyl acetate is added and the mixture is washed with sat. aqueous NaHCO3 solution and brine. The organic layer is dried over Na2SO4 and the solvents are removed in vacuo. THF (2.0 mL) and a solution of HCl in isopropanol (5-6 M, 0.10 mL) are added to the crude product and the solvents are removed in vacuo. The obtained solid is recrystallized from THF (2.0 mL) to give the desired amide as white crystals.
Datas are given for the free base of the more active diastereoisomer (IC50, FLIPR). Rf = 0.21 (EA/heptane 2/1);
LC-MS: rt = 0.90 min, 513 (M+l, ES+);
Chiral HPLC: rt = 18.9 min (hexane/ethanol 95/5; diastereoisomer: rt = 22.3 min; the two other possible stereoisomers with an opposite configuration in the 1,2,3,4-tetrahydro- isoquinoline ring system are prepared in analogy to the synthesis described above using N- ((lS,2S)-2-amino-l,2-diphenyl-ethyl)-2,4,6-trimethyl-benzene-sulfonamide (step G.2) for the transfer hydrogenation: these isomers have retention times of. rt = 26.2 min, 33.8 min);
Η-ΝMR (300MHz, CDC13): δ = 1.74-1.87 (m, IH), 2.04-2.19 (m, IH), 2.40-2.52 (m, IH), 2.59-2.72 (m, IH), 2.86 (d, J = 4.8 Hz, 3H), 2.86-3.01 (m, IH), 3.03-3.18 (m, 2H), 3.30-3.41 (m, 2H), 3.69 (s, 3H), 3.84 (s, 3H), 4.25 (s, IH), 6.03 (s, IH), 6.57 (s, IH), 6.87 (q, J = 4.8 Hz, IH), 7.10-7.16 (m, 2H), 7.19-7.28 (m, 5H), 7.50 (d, J = 8.1 Hz, 2H); 13 C-NMR (75MHz, CDC13): δ = 21.9, 26.1, 33.4, 37.8, 40.7, 55.8, 55.9, 57.0, 70.1, 1 10.0, 111.4, 124.2 (q, JC F = 271 Hz), 124.9, 125.1 (q, JC F = 4 Hz), 128.0 (q, JC;F = 32 Hz), 128.1, 128.4, 128.5, 129.0, 137.0, 146.2, 147.1, 147.6, 172.2.
Example 3: Synthesis of 2-(6,7-dimethoxy-l-r2-(6-trifluoromethyl-pyridin-3-yl)-ethyl'|-3,4- dihvdro-lH-isoquinolin-2-yl)-N-methyl-2-phenyl-acetamide
Figure imgf000031_0001
A mixture of {6,7-dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-lH- isoquinolin-2-yl}-phenyl-acetic acid (0.20 mmol), methylamine hydrochloride (0.20 mmol), PyBOP (0.20 mmol) and DIPEA (0.46 mmol) in DMF (1.0 mL) is stirred at RT for 20h.
Water and EA are added, the layers are separated and the aqueous layer is extracted with EA. The combined organic extracts are dried over MgSO4 and concentrated in vacuo. The residue is purified by flash chromatography (EA) to give the desired product as a viscous oil. LC-MS: rt = 1.17 min, 514 (M+l, ES+).
Example 4: Synthesis of (2R)-2-((lS)-6.7-dimethoxy-l-r2-(6-trifluoromethyl-pyridin-3-yl)- ethyll-3.4-dihydro-lH-isoquinolin-2-yl)-N-methyl-2-phenyl-acetamide
Figure imgf000031_0002
DIPEA (20.8 mmol) is added to a solution of (lS)-6,7-dimethoxy-l-[2-(6-trifluoromethyl- pyridin-3-yI)-ethyl]-l,2,3,4-tetrahydroisoquinoline (10.0 mmol) in THF (40 mL). 2-Bromo-N- methyl-2-phenyl-acetamide (10.4 mmol) is added and the mixture is stirred at 60°C for 5d. Water (100 mL) and ethyl acetate (200 mL) are added, the layers are separated and the aqueous layer is extracted twice with ethyl acetate (2x100 mL). The combined organic extracts are concentrated in vacuo and the residue is purified by flash chromatography (ethyl acetate/heptane 3/1) to give the desired amides as separated diastereoisomers. Data are given for the more active diastereoisomer (IC50, FLIPR).
Rf= 0.15 (EA/heptane 3/1);
LC-MS: rt = 0.81 min, 514 (M+l, ES+);
Η-NMR (300MHz, CDC13): δ = 1.73-1.86 ( , IH), 2.02-2.16 (m, IH), 2.41-2.52 (m, IH),
2.59-2.71 (m, IH), 2.87 (d, J = 5.1 Hz, 3H), 2.88-3.03 (m, IH), 3.04-3.17 (m, 2H), 3.26-3.36 (m, 2H), 3.69 (s, 3H), 3.83 (s, 3H), 4.23 (s, IH), 6.04 (s, IH), 6.55 (s, IH), 6.74 (q, J = 5.1 Hz, IH), 7.10-7.16 (m, 2H), 7.19-7.27 (m, 3H), 7.51-7.61 (m, 2H), 8.52 (s, IH).
Biological assays
In vitro assay
The orexin receptor antagonistic activity of the compounds of general formula (I) is determined in accordance with the following experimental method.
Experimental method:
• Intracellular calcium measurements:
Chinese hamster ovary (CHO) cells expressing the human orexin- 1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/ml G418, 100 U/ml penicillin, 100 μg/ml streptomycin and 10 % inactivated fetal calf serum (FCS). The cells are seeded at 80O00 cells / well into 96-well black clear bottom sterile plates (Costar) which have been precoated with 1% gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents are from Gibco BRL. The seeded plates are incubated overnight at 37CC in 5% CO2.
Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol: water (1 :1), diluted in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES.
On the day of the assay, 100 μl of loading medium (HBSS containing 1% FCS, 2 mM
HEPES, 5 mM probenecid (Sigma) and 3 μM of the fluorescent calcium indicator fluo-3 AM (1 mM stock solution in DMSO with 10% pluronic acid) (Molecular Probes) is added to each well.
The 96-well plates are incubated for 60 min at 37° C in 5% C02. The loading solution is then aspirated and cells are washed 3 times with 200 μl HBSS containing 2.5 mM probenecid, 0.1% BSA, 2 mM HEPES. 100 μl of that same buffer is left in each well. Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 50 μl, incubated for 20 min and finally 100 μl of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist. For each antagonist, IC50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. Antagonistic activities of compounds are in the nanomolar range.
• Measurements of the inhibitory potency against different CYPs: The CYP inhibition studies are performed using human liver microsomes (pool of 10 individuals), literature-established CYP isoform-selective substrates and quantification by either LC-MS/MS (for CYP3A4 and CYP2C9) or conventional HPLC with fluorimetric detection (for CYP2D6). The specific probes were midazolam l'-hydroxylation for CYP3A4, dextromethoφhan 3-hydroxylation for CYP2D6 and diclofenac 4'-hydroxylation for CYP2C9. Experiments were carried out in duplicate in 96-well plates with substrate concentrations around the respective Km values (Table 1 shows an overview of the experimental conditions) and 7 inhibitor concentrations up to 50 μM. Controls (sulfaphenazole for CYP2C9, fluoxetine for CYP2D6, and nicardipine for CYP3A4) were run in parallel in each plate.
Figure imgf000034_0001
Table 1 As illustrated in Table 2 hereinafter, compounds described in examples 1 to 4 show remarkably low affinities against CYP3A4.
Figure imgf000035_0001
Table! In vivo assay:
Spontaneous home cage activity and body temperature measured by radiotelemetry in laboratory rats:
The objective of the present test is to record the circadian behavioral activity of rats after oral administration of a compound according to general formula (I) of the invention.
Decreased home cage activity measured by telemetry in male Wistar rats was considered as an indication for sleep-inducing potential of a restricted number of highly optimized 1,2,3,4- tetrahydroisoquinoline derivatives.
Psychotropic drugs such as antidepressants, antipsychotics, sleep inducers or psychostimulants are well known to reduce or enhance home cage activity and body temperature following oral administration to laboratory animals. Thermoregulation is a complex process that contributes to homeostasis by coordinating metabolism, energy balance and behaviour. Body temperature changes with circadian behavioural activity and increases when locomotion increases. These two parameters were measured by telemetry in conscious freely moving Wistar rats. Anaesthetized animals were implanted, under aseptic conditions, with a body temperature/activity telemetric device into the peritoneal cavity. More than two weeks after the implantation of the telemetry system, data were collected at 5 minutes intervals during 96 hours. Hourly means were calculated for each rat. The first 48 h were used as an internal control trace and drug effects were compared to vehicle placebo. This method is validated pharmacologically by measuring amplitude and time course of both hypoactivity and hypothermia induced by GABA-A receptor modulators such as zolpidem.
As illustrated in Table 3 hereinafter, administration of orexin receptor antagonists of the present invention such as those described in examples 1 to 4 are orally active.
Figure imgf000037_0001
Table 3

Claims

Claims 1. 1 ,2,3,4-tetrahydroisoquinoline derivatives of the general formula (I)
Figure imgf000038_0001
(D wherein:
R1 and R2 independently represent hydrogen or C]-C4 alkoxy;
R3 represents Ci-Cδ-alkyl;
X represents -CH- or a nitrogen atom; and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts, solvent complexes and morphological forms, thereof.
2. 1,2,3,4-tetrahydroisoquinoline derivatives according to claim 1 wherein R and R both represent a Cι-C alkoxy group.
3. 1,2,3,4-tetrahydroisoquinoline derivatives according to claim 2 wherein R1 and R2 both represent a methoxy group.
4. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1 to 3 wherein X represents a nitrogen atom.
5. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1 to 3 wherein X represents -CH-.
6. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1 to 5 wherein R represents a methyl group.
7. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1, 2, 3 or 5 wherein R1 and R2 represent a methoxy group, X represents -CH- and R3 represents Ci-Cδ-alkyl.
8. A 1,2,3,4-tetrahydroisoquinoline derivative according to any of the claims 1 to 3 selected from the group consisting of: 2-{6,7-Dimethoxy-l- [2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-lH-iso-quinolin- 2-yl}-N-methyl-2-phenyl-acetamide; 2-{6,7-Dimethoxy-l-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-lH-iso- quinolin-2-yl}-N-methyl-2-phenyl-acetamide.
9. A 1,2,3,4-tetrahydroisoquinoline derivative according to any of the preceding claims for use as medicament.
10. A pharmaceutical composition containing at least one compound according to any of claims 1 to 8 and a pharmaceutically acceptable carrier material.
11. Use of a 1,2,3,4-tetrahydroisoquinoline derivative according to any of claims 1 to 8 in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Ηuntington's disease and Tourette syndrome; diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hypeφrolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hypeφrolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. by ΗIV; post-chemotherapy pain; post- stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; eating disorders; cardiovascular disorders; neurodegenerative disorders; sleep apnea; narcolepsy; insomnia; parasomnia; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy, seizure disorders and other diseases related to general orexin system dysfunctions.
12. Use according to claim 11 wherein said diseases are selected from the group consisting of eating disorders or sleep disorders.
13. Use according to claim 12 wherein said eating disorders comprise metabolic dysfunction, dysregulated appetite control, compulsive obesities, emeto-bulimia or anorexia nervosa.
14. Use according to claim 12 wherein said sleep disorders comprise insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome.
PCT/EP2005/001879 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives WO2005118548A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2005250077A AU2005250077B2 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
NZ550216A NZ550216A (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
PL05804734T PL1751111T3 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
ES05804734.1T ES2533389T3 (en) 2004-03-01 2005-02-23 1,2,3,4-tetrahydroisoquinoline derivatives substituted
DK05804734.1T DK1751111T3 (en) 2004-03-01 2005-02-23 SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives
SI200531944T SI1751111T1 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2007501172A JP4094050B2 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
BRPI0508263-3 BRPI0508263B8 (en) 2004-03-01 2005-02-23 1, 2, 3,4-tetrahydro-isoquinoline derivatives, pharmaceutical composition, and use of 1, 2, 3,4-tetrahydro-isoquinoline derivative
CN200580006491XA CN1926109B (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US10/598,449 US7763638B2 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
CA2557163A CA2557163C (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EP05804734.1A EP1751111B1 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
IL177798A IL177798A (en) 2004-03-01 2006-08-31 (2r)-2-{(1s)-6,7 dimethoxy-1-[2-[4-trifluoromethyl-phenyl) -ethyl]-3,4-dihydro-1h-isoquinolin-2-yl}-n- methyl-2-phenyl-acetamide, pharmaceutical compositions comprising it, uses thereof in the preparation of a medicament for the prevention or treatment of eating or sleep disorders and preparation of the hydrochloric acid salt crystalline form thereof
NO20064347A NO337299B1 (en) 2004-03-01 2006-09-26 A substituted 1,2,3,4-tetrahydroisoquinoline derivative and its use as a drug
US12/815,605 US20100256182A1 (en) 2004-03-01 2010-06-15 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
HRP20150371TT HRP20150371T1 (en) 2004-03-01 2015-03-30 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2004/002020 2004-03-01
EP2004002020 2004-03-01

Publications (1)

Publication Number Publication Date
WO2005118548A1 true WO2005118548A1 (en) 2005-12-15

Family

ID=34960649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001879 WO2005118548A1 (en) 2004-03-01 2005-02-23 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives

Country Status (24)

Country Link
US (2) US7763638B2 (en)
EP (1) EP1751111B1 (en)
JP (1) JP4094050B2 (en)
KR (1) KR100848747B1 (en)
CN (1) CN1926109B (en)
AR (1) AR047823A1 (en)
AU (1) AU2005250077B2 (en)
BR (1) BRPI0508263B8 (en)
CA (1) CA2557163C (en)
CY (1) CY1116103T1 (en)
DK (1) DK1751111T3 (en)
ES (1) ES2533389T3 (en)
HR (1) HRP20150371T1 (en)
IL (1) IL177798A (en)
MY (1) MY144992A (en)
NO (1) NO337299B1 (en)
NZ (1) NZ550216A (en)
PL (1) PL1751111T3 (en)
PT (1) PT1751111E (en)
RU (1) RU2378257C2 (en)
SI (1) SI1751111T1 (en)
TW (1) TWI301129B (en)
WO (1) WO2005118548A1 (en)
ZA (1) ZA200606974B (en)

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007105177A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
WO2007116374A1 (en) * 2006-04-11 2007-10-18 Actelion Pharmaceuticals Ltd Novel sulfonamide compounds
WO2007122591A3 (en) * 2006-04-26 2008-01-10 Actelion Pharmaceuticals Ltd Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008069997A1 (en) 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
WO2008122513A1 (en) 2007-04-04 2008-10-16 F. Hoffmann-La Roche Ag Heterocycles as orexin antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2009006859A2 (en) * 2007-07-09 2009-01-15 Zentiva A.S. A method of manufacturing 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7- tetrahydrothieno[3,2-c]pyridin-2-yl acetate (prasugrel)
WO2009047723A2 (en) 2007-10-10 2009-04-16 Actelion Pharmaceuticals Ltd Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
WO2009079637A1 (en) * 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
WO2009083903A1 (en) * 2007-12-28 2009-07-09 Actelion Pharmaceuticals Ltd Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
WO2009083899A2 (en) * 2007-12-28 2009-07-09 Actelion Pharmaceuticals Ltd Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
WO2009153180A1 (en) 2008-06-16 2009-12-23 F. Hoffmann-La Roche Ag Heteroaromatic monoamides as orexinin receptor antagonists
JP2010513466A (en) * 2006-12-22 2010-04-30 アクテリオン ファーマシューティカルズ リミテッド 5,6,7,8-tetrahydro-imidazo [1,5-A] pyrazine derivatives
JP2010514751A (en) * 2006-12-28 2010-05-06 アクテリオン ファーマシューティカルズ リミテッド 2-Aza-bicyclo [3.1.0] hexane derivatives as orexin receptor antagonists
WO2010064212A1 (en) 2008-12-05 2010-06-10 Actelion Pharmaceuticals Ltd Method for obtaining an optically pure 1,2,3,4 tetrahydro-isoquinoline derivative
WO2010072722A1 (en) 2008-12-23 2010-07-01 Glaxo Group Limited Piperidine derivatives useful as orexin antagonists
WO2010095106A1 (en) 2009-02-20 2010-08-26 Actelion Pharmaceuticals Ltd Solid forms of ( 2r) -2- { ( is ) -6, 7 -dimethoxy- 1- [2- (4-triflu0r0methyl-phenyl) -ethyl] -3, 4-dihydr0-1h -isoquinolin-2-yl} -n-methyl-2-phenyl-acetamide hydrochloride
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011001373A1 (en) 2009-06-30 2011-01-06 Actelion Pharmaceuticals Ltd Process for the preparation of an enantiomerically pure trisubstituted 1,2,3,4-tetrahydroisoquinoline derivative
WO2011005636A1 (en) * 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
WO2011047643A1 (en) 2009-10-19 2011-04-28 Zentiva, K.S. Method for the preparation of (ls)-6,7-dimethoxy-l-[2-(4-trifluoromethylphenyl)ethyl]- 1,2,3,4-tetrahydroisoquinoline
WO2011063773A2 (en) 2009-11-25 2011-06-03 Zentiva, K.S. Crystalline and amorphous forms of almorexant and a method of their preparation
WO2011082700A1 (en) 2010-01-05 2011-07-14 Zentiva, K.S. A method for the preparation of 6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)ethyl]-3,4- dihydroisoquinoline
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
WO2012025877A1 (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
US8133908B2 (en) 2008-12-02 2012-03-13 Glaxo Group Limited Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
WO2012039371A1 (en) 2010-09-22 2012-03-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Cyclopropane compound
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
CN101402643B (en) * 2008-11-11 2012-11-28 上海现代制药股份有限公司 Industrial production method for prasugrel
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2013068935A1 (en) 2011-11-08 2013-05-16 Actelion Pharmaceuticals Ltd 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
WO2013182972A1 (en) 2012-06-04 2013-12-12 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
EP2696872A4 (en) * 2011-04-01 2015-03-11 Univ Indiana Res & Tech Corp Treatment of glaucoma
WO2015083070A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
WO2015083071A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9789102B2 (en) 2012-04-06 2017-10-17 Sanofi H3 receptor antagonist for use in the treatment of alzheimer's disease
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US10188652B2 (en) 2014-10-23 2019-01-29 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10377763B2 (en) 2015-10-29 2019-08-13 University Of Tsukuba Morphinan derivative and medical usage thereof
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11059828B2 (en) 2009-10-23 2021-07-13 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751111B1 (en) * 2004-03-01 2014-12-31 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP5100298B2 (en) * 2007-10-11 2012-12-19 株式会社トクヤマ Optically active α-sulfonyloxycarboxylic acid amide derivative and method for producing the same
CN102076694A (en) * 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5, 6, 7, 8-tetrahydro-imidazo[1, 5-a]pyrazine compounds
CN103201261A (en) 2010-11-10 2013-07-10 埃科特莱茵药品有限公司 Lactam derivatives useful as orexin receptor antagonists
KR101671008B1 (en) * 2016-04-13 2016-12-01 한국과학기술원 Composition for appetite control containing N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine or pharmaceutically acceptable salts thereof as an active ingredient
CN110117271A (en) * 2018-02-06 2019-08-13 中国科学院上海药物研究所 Tetrahydroisoquinolicompounds compounds, preparation method, the medical composition and its use comprising such compound
CN117126134A (en) * 2022-05-20 2023-11-28 中国科学院上海药物研究所 Novel tetrahydroisoquinoline compounds, preparation method thereof, pharmaceutical composition containing compounds and application of compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068609A1 (en) * 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2002051838A1 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480714A (en) 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
DD204917A1 (en) 1981-12-31 1983-12-14 Gerhard Kempter METHOD FOR PRODUCING PHENYL SUBSTITUTED AND BENZ-CONDENSED CYCLOALKYLAMINOACETANILIDES
DE3419642A1 (en) 1984-05-25 1985-11-28 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD AND REAGENT FOR FULLY ENZYMATIC DETERMINATION OF UREA
JPS6153268A (en) 1984-08-24 1986-03-17 Hokuriku Seiyaku Co Ltd Anthranilamide derivative
DD261158A1 (en) 1987-01-08 1988-10-19 Univ Halle Wittenberg PROCESS FOR THE PREPARATION OF 2-AMINOALKYL-3,4-DIHYDRO-4-OXO-7H-PYRROLO 2.3-D PYRIMIDINES
DD258817A1 (en) 1987-01-19 1988-08-03 Univ Halle Wittenberg PROCESS FOR PREPARING 2- (AMINOALKYL) -PYRIMIDO-4,5'-5,4 PYRROLO 3,2-F 1,4 THIAZEPINE DERIVATIVES
WO1992012132A1 (en) 1991-01-11 1992-07-23 Laboratoires Glaxo S.A. Acridine derivatives
JPH07267961A (en) 1994-03-30 1995-10-17 Taisho Pharmaceut Co Ltd Benzofuro (3,2-d)pyrimidine-4-one derivative
DE69635874T2 (en) 1995-12-06 2006-12-14 Japan Science And Technology Agency, Kawaguchi Process for the preparation of optically active alcohols
ATE256739T1 (en) 1996-08-02 2004-01-15 Scripps Research Inst HYPOTHALAMUS-SPECIFIC POLYPEPTIDES
JPH1095766A (en) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd Acetamide derivative and its use
KR100334567B1 (en) 1996-11-27 2002-05-03 디. 제이. 우드, 스피겔 알렌 제이 Apo-b-secretion/mtp inhibitory amides
AR016817A1 (en) 1997-08-14 2001-08-01 Smithkline Beecham Plc DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
WO2000029399A1 (en) 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
GB9827467D0 (en) 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
GB9914015D0 (en) 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
ATE241345T1 (en) 1999-02-12 2003-06-15 Smithkline Beecham Plc NEW USE OF OREXIN RECEPTOR ANTAGONISTS
DE60013250T2 (en) 1999-02-12 2005-09-08 Smithkline Beecham P.L.C., Brentford Phenylurea and phenylthiourea derivatives as orexin receptor antagonists
US6596730B1 (en) 1999-02-12 2003-07-22 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
GB9914025D0 (en) 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
JP2003503480A (en) 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド N-heterocyclic derivatives having neuronal activity
AU6615300A (en) 1999-07-30 2001-02-19 Board Of Trustees Of The Leland Stanford Junior University Hypocretin and hypocretin receptors in regulation of sleep and related disorders
US6319710B1 (en) 1999-08-23 2001-11-20 Decode Genetics Ehf. Human narcolepsy gene
US6410712B1 (en) 1999-10-25 2002-06-25 Decode Genetics Ehf. Human narcolepsy gene
WO2001040304A1 (en) 1999-12-01 2001-06-07 Smithkline Beecham Corporation Monkey orexin 2 receptor
WO2001040259A2 (en) 1999-12-02 2001-06-07 Smithkline Beecham Corporation Monkey orexin 1 receptor
US20020064814A1 (en) 1999-12-07 2002-05-30 Ellis Catherine E. Dog orexin 1 receptor
WO2001074162A1 (en) 2000-04-04 2001-10-11 The Regents Of The University Of California Treatment of sleep disorders with hypocretin-1
WO2001085693A1 (en) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
ES2234929T3 (en) 2000-11-28 2005-07-01 Smithkline Beecham Plc MORFOLINE DERIVATIVES AS ANTAGONISTS OF OREXINE RECEPTORS.
AU2001297807A1 (en) 2000-12-20 2002-11-11 Sri International Modulators of the hypocretin system and methods of screening therefor
US20040192673A1 (en) 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
AU2002253361B2 (en) 2001-05-05 2006-08-17 Smithkline Beecham P.L.C. N-aroyl cyclic amines
MXPA03011706A (en) 2001-06-28 2004-03-19 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists.
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130388D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
PT1501804E (en) 2002-04-26 2009-10-29 Hoffmann La Roche Isoquinoline derivatives mao-b inhibitors
AU2003262963A1 (en) 2002-08-29 2004-03-19 The Regents Of The University Of California Hypocretin administration as a treatment for obesity
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
WO2004052876A1 (en) 2002-12-12 2004-06-24 Janssen Pharmaceutica, N.V. Substituted 4-phenyl-[1,3]-dioxanes
EP1572133B1 (en) 2002-12-13 2008-04-09 Janssen Pharmaceutica N.V. Method for identifying modulators of human orexin-2 receptor
EP1751111B1 (en) * 2004-03-01 2014-12-31 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP4582722B2 (en) 2006-03-15 2010-11-17 アクテリオン ファーマシューティカルズ リミテッド Tetrahydroisoquinoline derivatives that improve memory function
DE602007012072D1 (en) 2006-04-26 2011-03-03 Actelion Pharmaceuticals Ltd ORANTAGONISTEN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068609A1 (en) * 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2002051838A1 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007105177A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
KR101065239B1 (en) 2006-03-15 2011-09-16 액테리온 파마슈티칼 리미티드 Tetrahydroisoquinoline derivatives to enhance memory function
EA015256B1 (en) * 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Tetrahydroisoquinoline derivatives to enhance memory function
WO2007116374A1 (en) * 2006-04-11 2007-10-18 Actelion Pharmaceuticals Ltd Novel sulfonamide compounds
US8003654B2 (en) 2006-04-11 2011-08-23 Actelion Pharmaceuticals Ltd. N-glycinsulfonamide derivatives and uses as orexin receptor antagonists
JP2009535324A (en) * 2006-04-26 2009-10-01 アクテリオン ファーマシューティカルズ リミテッド Novel pyrazolo-tetrahydropyridine derivatives
WO2007122591A3 (en) * 2006-04-26 2008-01-10 Actelion Pharmaceuticals Ltd Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
US7834028B2 (en) 2006-04-26 2010-11-16 Actelion Pharmaceuticals Ltd. Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008069997A1 (en) 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
EP2392572A1 (en) 2006-12-01 2011-12-07 Merck Sharp & Dohme Corp. Substituted diazepan compounds as orexin receptor antagonists
US7951797B2 (en) 2006-12-01 2011-05-31 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
JP2010513466A (en) * 2006-12-22 2010-04-30 アクテリオン ファーマシューティカルズ リミテッド 5,6,7,8-tetrahydro-imidazo [1,5-A] pyrazine derivatives
US8188082B2 (en) 2006-12-22 2012-05-29 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives
JP2010514751A (en) * 2006-12-28 2010-05-06 アクテリオン ファーマシューティカルズ リミテッド 2-Aza-bicyclo [3.1.0] hexane derivatives as orexin receptor antagonists
US8067598B2 (en) 2007-04-04 2011-11-29 Hoffman-La Roche Inc. Heterofused piperidines as orexin antagonists
AU2008235528B2 (en) * 2007-04-04 2012-11-08 F. Hoffmann-La Roche Ag Heterocycles as orexin antagonists
JP2010523518A (en) * 2007-04-04 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー Heterocycles as orexin antagonists
WO2008122513A1 (en) 2007-04-04 2008-10-16 F. Hoffmann-La Roche Ag Heterocycles as orexin antagonists
KR101158976B1 (en) 2007-04-04 2012-06-21 에프. 호프만-라 로슈 아게 Heterocycles as orexin antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
US8242121B2 (en) 2007-05-23 2012-08-14 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
US8569311B2 (en) 2007-05-23 2013-10-29 Merch Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
EA016207B1 (en) * 2007-07-09 2012-03-30 ЗЕНТИВА, а.с. A method of manufacturing 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate (prasugrel)
WO2009006859A3 (en) * 2007-07-09 2009-03-19 Zentiva As A method of manufacturing 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7- tetrahydrothieno[3,2-c]pyridin-2-yl acetate (prasugrel)
CZ302135B6 (en) * 2007-07-09 2010-11-10 Zentiva, A. S. Process for preparing 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4, 5, 6, 7-tetrahydrothieno[3,2-c]-pyridin-2-yl acetate (prasugrel)
WO2009006859A2 (en) * 2007-07-09 2009-01-15 Zentiva A.S. A method of manufacturing 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7- tetrahydrothieno[3,2-c]pyridin-2-yl acetate (prasugrel)
WO2009047723A2 (en) 2007-10-10 2009-04-16 Actelion Pharmaceuticals Ltd Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
EA017443B1 (en) * 2007-10-10 2012-12-28 Актелион Фармасьютиклз Лтд. Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
AU2008309194B2 (en) * 2007-10-10 2013-10-03 Idorsia Pharmaceuticals Ltd Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
WO2009047723A3 (en) * 2007-10-10 2009-05-28 Actelion Pharmaceuticals Ltd Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
US8084464B2 (en) * 2007-12-18 2011-12-27 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
WO2009079637A1 (en) * 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
WO2009083903A1 (en) * 2007-12-28 2009-07-09 Actelion Pharmaceuticals Ltd Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
US20100305325A1 (en) * 2007-12-28 2010-12-02 Erhard Bappert Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
WO2009083899A2 (en) * 2007-12-28 2009-07-09 Actelion Pharmaceuticals Ltd Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
US8247560B2 (en) 2007-12-28 2012-08-21 Actelion Pharmaceuticals Ltd. Trisubstituted 3,4-dihydro-1H-isoquinolin compound, process for its preparation, and its use
KR101579991B1 (en) 2007-12-28 2015-12-23 액테리온 파마슈티칼 리미티드 Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
US8314238B2 (en) 2007-12-28 2012-11-20 Actelion Pharmaceuticals Ltd. Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
KR20100108411A (en) * 2007-12-28 2010-10-06 액테리온 파마슈티칼 리미티드 Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
WO2009083899A3 (en) * 2007-12-28 2009-08-20 Actelion Pharmaceuticals Ltd Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative
US8133909B2 (en) 2008-06-16 2012-03-13 Hoffmann-La Roche Inc. Heteroaromatic monoamides as orexinin receptor antagonists
WO2009153180A1 (en) 2008-06-16 2009-12-23 F. Hoffmann-La Roche Ag Heteroaromatic monoamides as orexinin receptor antagonists
CN101402643B (en) * 2008-11-11 2012-11-28 上海现代制药股份有限公司 Industrial production method for prasugrel
US8133908B2 (en) 2008-12-02 2012-03-13 Glaxo Group Limited Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
WO2010064212A1 (en) 2008-12-05 2010-06-10 Actelion Pharmaceuticals Ltd Method for obtaining an optically pure 1,2,3,4 tetrahydro-isoquinoline derivative
WO2010072722A1 (en) 2008-12-23 2010-07-01 Glaxo Group Limited Piperidine derivatives useful as orexin antagonists
WO2010095106A1 (en) 2009-02-20 2010-08-26 Actelion Pharmaceuticals Ltd Solid forms of ( 2r) -2- { ( is ) -6, 7 -dimethoxy- 1- [2- (4-triflu0r0methyl-phenyl) -ethyl] -3, 4-dihydr0-1h -isoquinolin-2-yl} -n-methyl-2-phenyl-acetamide hydrochloride
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011001373A1 (en) 2009-06-30 2011-01-06 Actelion Pharmaceuticals Ltd Process for the preparation of an enantiomerically pure trisubstituted 1,2,3,4-tetrahydroisoquinoline derivative
WO2011005636A1 (en) * 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
WO2011047643A1 (en) 2009-10-19 2011-04-28 Zentiva, K.S. Method for the preparation of (ls)-6,7-dimethoxy-l-[2-(4-trifluoromethylphenyl)ethyl]- 1,2,3,4-tetrahydroisoquinoline
USRE48841E1 (en) 2009-10-23 2021-12-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US11667644B2 (en) 2009-10-23 2023-06-06 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US11059828B2 (en) 2009-10-23 2021-07-13 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
WO2011063773A3 (en) * 2009-11-25 2012-02-02 Zentiva, K.S. Crystalline and amorphous forms of almorexant hydrochloride and a method of their preparation
WO2011063773A2 (en) 2009-11-25 2011-06-03 Zentiva, K.S. Crystalline and amorphous forms of almorexant and a method of their preparation
WO2011082700A1 (en) 2010-01-05 2011-07-14 Zentiva, K.S. A method for the preparation of 6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)ethyl]-3,4- dihydroisoquinoline
CZ302637B6 (en) * 2010-01-05 2011-08-10 Zentiva, K. S Process for preparing 6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)ethyl]-3-4-dihydroisoquinoline
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
US8895606B2 (en) 2010-08-24 2014-11-25 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
WO2012025877A1 (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
US9211279B2 (en) 2010-08-24 2015-12-15 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
US9000029B2 (en) 2010-08-24 2015-04-07 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
WO2012039371A1 (en) 2010-09-22 2012-03-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Cyclopropane compound
US8268848B2 (en) 2010-09-22 2012-09-18 Eisai R&D Management Co., Ltd. Cyclopropane compound
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9303023B2 (en) 2011-02-18 2016-04-05 Actelion Pharmaceuticals Ltd. Pyrazole and imidazole derivatives useful as orexin antagonists
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
EP2696872A4 (en) * 2011-04-01 2015-03-11 Univ Indiana Res & Tech Corp Treatment of glaucoma
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US9156819B2 (en) 2011-10-19 2015-10-13 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2013068935A1 (en) 2011-11-08 2013-05-16 Actelion Pharmaceuticals Ltd 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9896452B2 (en) 2012-02-07 2018-02-20 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9789102B2 (en) 2012-04-06 2017-10-17 Sanofi H3 receptor antagonist for use in the treatment of alzheimer's disease
WO2013182972A1 (en) 2012-06-04 2013-12-12 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
US9732075B2 (en) 2012-06-04 2017-08-15 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US11040966B2 (en) 2012-06-04 2021-06-22 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US10329287B2 (en) 2012-06-04 2019-06-25 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
US10023560B2 (en) 2013-12-03 2018-07-17 Idorsia Pharmaceuticals Ltd Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
US9914720B2 (en) 2013-12-03 2018-03-13 Idorsia Pharmaceuticals Ltd Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
WO2015083071A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
US9790208B2 (en) 2013-12-03 2017-10-17 Idorsia Pharmaceuticals Ltd Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2015083070A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10702529B2 (en) 2014-10-23 2020-07-07 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
US11026944B2 (en) 2014-10-23 2021-06-08 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
US10188652B2 (en) 2014-10-23 2019-01-29 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
US10377763B2 (en) 2015-10-29 2019-08-13 University Of Tsukuba Morphinan derivative and medical usage thereof
US12084437B2 (en) 2016-02-12 2024-09-10 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11434236B2 (en) 2016-02-12 2022-09-06 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11241432B2 (en) 2016-03-10 2022-02-08 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Also Published As

Publication number Publication date
KR20060123785A (en) 2006-12-04
BRPI0508263A (en) 2007-07-31
US7763638B2 (en) 2010-07-27
TWI301129B (en) 2008-09-21
US20100256182A1 (en) 2010-10-07
IL177798A0 (en) 2006-12-31
KR100848747B1 (en) 2008-07-25
CN1926109B (en) 2011-04-13
CY1116103T1 (en) 2017-02-08
US20070191424A1 (en) 2007-08-16
JP2007525531A (en) 2007-09-06
PT1751111E (en) 2015-04-01
PL1751111T3 (en) 2015-06-30
CA2557163A1 (en) 2005-12-15
AU2005250077B2 (en) 2011-06-09
NZ550216A (en) 2009-08-28
ES2533389T3 (en) 2015-04-09
SI1751111T1 (en) 2015-04-30
NO337299B1 (en) 2016-03-07
NO20064347L (en) 2006-09-26
BRPI0508263B1 (en) 2018-08-21
EP1751111A1 (en) 2007-02-14
AR047823A1 (en) 2006-02-22
EP1751111B1 (en) 2014-12-31
ZA200606974B (en) 2008-04-30
IL177798A (en) 2012-08-30
BRPI0508263B8 (en) 2021-05-25
RU2006134624A (en) 2008-04-10
MY144992A (en) 2011-12-15
CN1926109A (en) 2007-03-07
TW200533663A (en) 2005-10-16
HRP20150371T1 (en) 2015-05-08
RU2378257C2 (en) 2010-01-10
AU2005250077A1 (en) 2005-12-15
JP4094050B2 (en) 2008-06-04
CA2557163C (en) 2011-08-16
DK1751111T3 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
EP1751111B1 (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EP1611104B1 (en) Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US7192950B2 (en) Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
US6703392B2 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
EP2013209B1 (en) Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists
AU2001260113A1 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
US7538109B2 (en) Quinoxalin-3-one derivatives as orexin receptor antagonists
JP2008526906A (en) Substituted 4-phenyltetrahydroisoquinolines, methods for their preparation, their use as drugs and drugs containing them
MXPA06009833A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EP1620409B1 (en) Quinoxalin-3-one derivatives as orexin receptor antagonists
EP1274687B1 (en) 1,2,3,4- tetrahydroisoquinoline derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005804734

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006/06974

Country of ref document: ZA

Ref document number: 200606974

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2557163

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007501172

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009833

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10598449

Country of ref document: US

Ref document number: 2007191424

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200580006491.X

Country of ref document: CN

Ref document number: 12006501690

Country of ref document: PH

Ref document number: 177798

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 3637/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067020299

Country of ref document: KR

Ref document number: 2005250077

Country of ref document: AU

Ref document number: 550216

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006134624

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005250077

Country of ref document: AU

Date of ref document: 20050223

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005250077

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067020299

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005804734

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0508263

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10598449

Country of ref document: US